Bosutinib is Src/Abl dual tyrosine kinase inhibitor yakatenderwa kurapwa kweachangobva kubatwa chirwere chisingaperi (CP) chisingaperi myelogenous leukemia (CML), kana kuramba kana kusashivirira kurapwa kwekare CML. Chidzidzo chacho chakaenzanisa data kubva mumutsara wekutanga besutinib uye imatinib mishonga pa ≥24 mwedzi yekutevera. BFORE inoenderera mberi, yakavhurika-label chikamu III chekiriniki yekudzidza ine huwandu hwevarwere ve536 vakanyoresa uye vasina kurongeka vakapihwa kugamuchira bursatinib (n = 268) kana imatinib (n = 268) mune 1: 1 reshiyo kurapwa.
At a follow-up of 12 months, compared with the imatinib group, the bosutinib group showed higher molecular remission (MR) and complete cytogenetic remission (CCyR). Uye uyu mutsauko wakaramba uchitevera mushure memwedzi makumi maviri nemana. Pamwedzi makumi maviri nemana yekutevera, iwo mapoka maviri akaratidzira musiyano wakakura wekuregererwa (MMR), asi mutsauko uripakati paMR24 neMR24 wanga usina kukosha. Kuenzaniswa neboka imatinib, iyo nguva yekusvika MR uye CCyR yaive ipfupi muboka re bosutinib. Varwere vatanhatu muboka rebututinib uye varwere vanomwe muboka re imatinib vakashandurwa kuenda kuchikamu chinokurumidza / chinokurumidza. Pamwedzi makumi maviri nemana yekutevera, zvichienzaniswa neboka re imatinib, iro boka re bosutinib rakaratidza hukuru hukuru hwema molecular remission (MMR). Zvidzidzo zvinotsigira kushandiswa kwe bosutinib mune yekutanga-kurapwa kurapwa kwevarwere veCCPLL.
